Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Prominent Romanian painters include: Nicolae Grigorescu, Ștefan Luchian, Ion Andreescu Nicolae Tonitza, and Theodor Aman. Notable Romanian classical composers of the 19th and 20th centuries include: Ciprian Porumbescu, Anton Pann, Eduard Caudella, Mihail Jora, Dinu Lipatti, and especially George Enescu. The annual George Enescu Festival is held in Bucharest in honour of the 20th-century composer. Contemporary musicians like Angela Gheorghiu, Gheorghe Zamfir, Inna, Alexandra Stan, and many others have achieved various levels of international acclaim. From the late 2000s through the early 2010s, the Romanian popcorn music style had established itself in the international mainstream. At the Eurovision Song Contest Romanian singers achieved third place in 2005 and 2010. In cinema, several movies of the Romanian New Wave have achieved international acclaim. At the Cannes Film Festival, The Death of Mr. Lazarescu by Cristi Puiu won the Prix Un Certain Regard in 2005, while 4 Months, 3 Weeks and 2 Days by Cristian Mungiu won the festival's top prize, the Palme d'Or, in 2007. At the Berlin International Film Festival, Child's Pose by Călin Peter Netzer won the Golden Bear in 2013. The list of World Heritage Sites includes six cultural sites located within Romania, including eight painted churches of northern Moldavia, eight wooden churches of Maramureș, seven villages with fortified churches in Transylvania, the Horezu Monastery, and the Historic Centre of Sighișoara.
Damage to the basal ganglia can cause the release or reinstatement of the inhibitions to be erratic and uncontrolled, which results in an awkward start to the motion or motions to be unintentionally initiated or in a motion to be halted before or beyond its intended completion. The accumulating damage to this area causes the characteristic erratic movements associated with HD, known as chorea, a dyskinesia. Because of the basal ganglia's inability to inhibit movements, individuals affected by it inevitably experience a reduced ability to produce speech and swallow foods and liquids (dysphagia).
=== Spinal leak === The vast majority of CSF leaks are spinal. Spinal leaks occur when one or more holes form in the dura along the spinal cord. There are three types of spontaneous spinal CSF leaks. A spinal leak typically causes spontaneous intracranial hypotension.
Sources: en.wikipedia.org
A Novichok agent was used in 1995 to poison Russian banker Ivan Kivelidi, who died three days later in a hospital at the age of 46. The poison was believed to have been applied to Kivelidi's office phone in Moscow. His secretary Zara Ismailova also developed symptoms one month later and then died a day later in a hospital at the age of 35. Kivelidi was the head of the Russian Business Round Table, and had close ties to Viktor Chernomyrdin, who was at that time Prime Minister of Russia. Russian opposition–linked historians Yuri Felshtinsky and Vladimir Pribylovsky speculated that the murder became "one of the first in the series of poisonings organised by Russia's security services". The Russian Ministry of Internal Affairs analysed the substance and announced that it was "a phosphorus-based military-grade nerve agent" "whose formula was strictly classified". According to Nesterov, the administrative head of Shikhany, he did not know of "a single case of such poison being sold illegally" and noted that the poison "is used by professional spies". Vladimir Khutsishvili, a former business partner of Kivelidi's, was subsequently convicted of the killings. According to The Independent, "A closed trial found that his business partner had obtained the substance via intermediaries from an employee of the State Research Institute of Organic Chemistry and Technology (ГосНИИОХТ / GosNIIOKhT), which was involved in the development of Novichok agents. However, Khutsishvili, who claimed that he was innocent, had not been detained at the time of the trial and freely left the country.
==== Biden administration ==== On 13 February 2021, the White House said it had "deep concerns" about both the way the WHO's findings were communicated and the process used to reach them. Mirroring concerns raised by the Trump administration, National Security Advisor Jake Sullivan stated that it was essential that the WHO-convened report be independent and "free from alteration by the Chinese government". On 14 April 2021, the Director of National Intelligence Avril Haines, along with other Biden administration officials, said that they had not ruled out the possibility of a laboratory accident as the origin of the COVID-19 virus. On 26 May 2021, President Joe Biden directed the U.S. intelligence community to produce a report within 90 days on whether the COVID-19 virus originated from human contact with an infected animal or from an accidental lab leak, stating his national security staff said there is insufficient evidence to determine either hypothesis to be more likely. On 26 August 2021, the Office of the Director of National Intelligence released an unclassified summary of their findings, with the main point being that the report remained inconclusive as to the origin of the virus, with intelligence agencies divided on the question. The report also concluded that the virus was most likely not genetically engineered, and that China had no foreknowledge of the virus prior to the outbreak.
=== The degree of crystallinity and crystal structure of nanocellulose. === Nanocellulose exhibits cellulose crystal I organization and the degree of crystallinity is unchanged by the preparation of the nanocellulose. Typical values for the degree of crystallinity were around 63%.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。